See-Saw: Challenger Natco Is Now Licensee For Lilly’s Baricitinib
Executive Summary
Lilly brings challenger Natco into licensee fold for baricitinib in COVID-19, while the Indian firm retracts a compulsory licensing application for the JAK inhibitor, rapidly diffusing a potentially difficult situation for both sides. But will the six other baricitinib licensees in India match the price of Natco’s on-market version?
You may also be interested in...
South Africa Urged To Revoke Key COVID-19 Patents
Eli Lilly’s Olumiant (baricitinib) patent in South Africa is unjustifiably preventing generics manufacturers from selling cheaper versions of the product in the country, NGO MSF insists. The arthritis drug has been recommended by the WHO as a treatment for severe and critical cases of COVID-19.
South Africa Must Revoke Key COVID-19 Patents, Says MSF
Eli Lilly’s Olumiant (baricitinib) patent in South Africa is unjustifiably preventing generics manufacturers from selling cheaper versions of the drug in the country, MSF insists. The arthritis drug has been recommended as a treatment for severe and critical cases of COVID-19 by the WHO.
Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments
Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.